• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (16)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Pacemakers/ Defibrillators  • Cardiovascular System  • Quality of Care  • Evidence-Based Medicine  • Women's Health  • Women's Health, Other  • Prognosis/ Outcomes  • Arrhythmias  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic  Social Bookmarking   What's this?

A Meta-analysis of Randomized Controlled Trials

Hamid Ghanbari, MD; Ghassan Dalloul, MD; Reema Hasan, MD; Marcos Daccarett, MD, MSc; Souheil Saba, MD; Shukri David, MD; Christian Machado, MD

Arch Intern Med. 2009;169(16):1500-1506.

Background  Numerous clinical trials have established a role for implantable cardioverter-defibrillators in the prevention of sudden cardiac death in patients with heart failure. However, questions remain that regard the clinical benefit of these therapies in different patient subgroups. Specifically, the role of implantable cardioverter-defibrillators in women with heart failure for the primary prevention of sudden cardiac death has not been well established. Our objective is to determine whether implantable cardioverter-defibrillators reduce mortality in women with advanced heart failure.

Methods  We searched MEDLINE (1950-2008), EMBASE (1988-2008, week 24), the Cochrane Controlled Trials Register (third quarter, 2008), the National Institute of Health ClinicalTrials.gov database, the Food and Drug Administration Web site, and various reports presented at scientific meetings (1994-2007). Eligible studies were randomized controlled trials of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with heart failure that reported all-cause mortality as an outcome for the female population. Of the 2619 reports identified, 5 trials that enroll 934 women were included in the meta-analysis.

Results  Pooled data from the 5 trials revealed no statistically significant decrease in all-cause mortality in women with heart failure who receive implantable cardioverter-defibrillators (hazard ratio, 1.01; 95% confidence interval, 0.76-1.33).

Conclusions  Implantable cardioverter-defibrillator therapy for the primary prevention of sudden cardiac death in women does not reduce all-cause mortality. Further studies are needed to investigate the reasons for this ob servation and to define the population of women who may benefit most from implantable cardioverter-defibrillator therapy.

Author Affiliations: Department of Cardiology, Providence Hospital Heart Institute and Medical Center, Southfield, Michigan.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

In This Issue of Archives of Internal Medicine
Arch Intern Med. 2009;169(16):1459.
FULL TEXT  

Is What Is Good for the Gander Really Good for the Goose?
Rita F. Redberg
Arch Intern Med. 2009;169(16):1460-1461.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sex Differences in Implantable Cardioverter-Defibrillator Outcomes: Findings From a Prospective Defibrillator Database
MacFadden et al.
ANN INTERN MED 2012;156:195-203.
ABSTRACT | FULL TEXT  

Is Biology Destiny or Can We Optimize Care for All Patients?
Douglas and Curtis
ANN INTERN MED 2012;156:241-242.
FULL TEXT  

Sudden cardiac death and implantable cardioverter defibrillators: two modern epidemics?
Katritsis and Josephson
Europace 2012;0:eus001v1-eus001.
ABSTRACT | FULL TEXT  

Clinical Trial Enrollment and Progress in Women's Health
Dhruva and Redberg
JAMA 2011;305:1197-1197.
FULL TEXT  

Gender Bias in Studies for Food and Drug Administration Premarket Approval of Cardiovascular Devices
Dhruva et al.
Circ Cardiovasc Qual Outcomes 2011;4:165-171.
ABSTRACT | FULL TEXT  

48 Cardiac resynchronization therapy
Chandrasekaran and Cowburn
Oxford Textbook of Heart Failure 2011;1:med-9780199577729-chapter-med-9780199577729-chapter.
ABSTRACT | FULL TEXT  

Heart Failure Guidelines, Performance Measures, and the Practice of Medicine: Mind the Gap
Ghali et al.
J Am Coll Cardiol 2010;56:2077-2080.
ABSTRACT | FULL TEXT  

Counting Performance With Therapies for Heart Failure: Aiming for Quality or Quantity?
Stevenson
Circulation 2010;122:561-566.
FULL TEXT  

Review Article: The New Concept of Interventional Heart Failure Therapy--Part 1: Electrical Therapy, Treatment of CAD, Fluid Removal, and Ventricular Support
Thompson et al.
J CARDIOVASC PHARMACOL THER 2010;15:102-111.
ABSTRACT  

Best Clinical Practice: Art, Science, or Both?: Comment on "Implantable Cardiac Device Procedures in Older Patients"
Kusumoto
Arch Intern Med 2010;170:638-639.
FULL TEXT  

Are Implanted Defibrillators Effective Therapy in the Elderly?: Asked, Not Answered
Havranek and Peterson
Circ Heart Fail 2010;3:4-6.
FULL TEXT  

Do ICDs Work Better for Men Than for Women?
JWatch Women's Health 2009;2009:6-6.
FULL TEXT  

Is What Is Good for the Gander Really Good for the Goose?
Redberg
Arch Intern Med 2009;169:1460-1461.
FULL TEXT